You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer

Article info

Article menu

Download PDFPDF

Research Article
Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer

Authors

  • May Tun Saung Department of OncologyJohns Hopkins University School of Medicine Baltimore MD USA The Sidney Kimmel Cancer CenterJohns Hopkins University School of Medicine Baltimore MD USA Pancreatic Cancer Precision Medicine ProgramJohns Hopkins University School of Medicine Baltimore MD USA The Bloomberg-Kimmel Institute for Cancer ImmunotherapyJohns Hopkins University School of Medicine Baltimore MD USA PubMed articlesGoogle scholar articles
  • Stephen Muth Department of OncologyJohns Hopkins University School of Medicine Baltimore MD USA The Sidney Kimmel Cancer CenterJohns Hopkins University School of Medicine Baltimore MD USA Pancreatic Cancer Precision Medicine ProgramJohns Hopkins University School of Medicine Baltimore MD USA The Bloomberg-Kimmel Institute for Cancer ImmunotherapyJohns Hopkins University School of Medicine Baltimore MD USA PubMed articlesGoogle scholar articles
  • Ding Ding Department of OncologyJohns Hopkins University School of Medicine Baltimore MD USA The Sidney Kimmel Cancer CenterJohns Hopkins University School of Medicine Baltimore MD USA Pancreatic Cancer Precision Medicine ProgramJohns Hopkins University School of Medicine Baltimore MD USA The Bloomberg-Kimmel Institute for Cancer ImmunotherapyJohns Hopkins University School of Medicine Baltimore MD USA PubMed articlesGoogle scholar articles
  • Dwayne L. Thomas Department of OncologyJohns Hopkins University School of Medicine Baltimore MD USA The Sidney Kimmel Cancer CenterJohns Hopkins University School of Medicine Baltimore MD USA Pancreatic Cancer Precision Medicine ProgramJohns Hopkins University School of Medicine Baltimore MD USA The Bloomberg-Kimmel Institute for Cancer ImmunotherapyJohns Hopkins University School of Medicine Baltimore MD USA PubMed articlesGoogle scholar articles
  • Alex B. Blair The Sidney Kimmel Cancer CenterJohns Hopkins University School of Medicine Baltimore MD USA Department of SurgeryJohns Hopkins University School of Medicine Baltimore MD USA Pancreatic Cancer Precision Medicine ProgramJohns Hopkins University School of Medicine Baltimore MD USA The Bloomberg-Kimmel Institute for Cancer ImmunotherapyJohns Hopkins University School of Medicine Baltimore MD USA PubMed articlesGoogle scholar articles
  • Takahiro Tsujikawa Department of Otolaryngology-Head and Neck SurgeryKyoto Prefectural University of Medicine Kyoto Japan Department of Cell, Developmental & Cancer BiologyOregon Health and Science University Portland OR USA PubMed articlesGoogle scholar articles
  • Lisa Coussens Department of Cell, Developmental & Cancer BiologyOregon Health and Science University Portland OR USA Knight Cancer InstituteOregon Health and Science University Portland OR USA PubMed articlesGoogle scholar articles
  • Elizabeth M. Jaffee Department of OncologyJohns Hopkins University School of Medicine Baltimore MD USA The Sidney Kimmel Cancer CenterJohns Hopkins University School of Medicine Baltimore MD USA The Skip Viragh Center for Pancreatic Cancer Research and Clinical CareJohns Hopkins University School of Medicine Baltimore MD USA Pancreatic Cancer Precision Medicine ProgramJohns Hopkins University School of Medicine Baltimore MD USA The Bloomberg-Kimmel Institute for Cancer ImmunotherapyJohns Hopkins University School of Medicine Baltimore MD USA PubMed articlesGoogle scholar articles
  • Lei Zheng Department of OncologyJohns Hopkins University School of Medicine Baltimore MD USA The Sidney Kimmel Cancer CenterJohns Hopkins University School of Medicine Baltimore MD USA Department of SurgeryJohns Hopkins University School of Medicine Baltimore MD USA The Skip Viragh Center for Pancreatic Cancer Research and Clinical CareJohns Hopkins University School of Medicine Baltimore MD USA Pancreatic Cancer Precision Medicine ProgramJohns Hopkins University School of Medicine Baltimore MD USA The Bloomberg-Kimmel Institute for Cancer ImmunotherapyJohns Hopkins University School of Medicine Baltimore MD USA PubMed articlesGoogle scholar articles

Citation

Saung MT, Muth S, Ding D, et al
Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer
Journal for ImmunoTherapy of Cancer 2018;6:118. doi: 10.1186/s40425-018-0435-6
Online issue publication 
February 10, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.